Table S8.

Dosage regimen of treatments

	Treatment	Dose	Regimen	Cycle duration (days)	Maximum number of cycles	References
ALK+ diagnosed patients	Alectinib (monotherapy)
	Alectinib	1200 mg	600 mg twice daily	30	Up to progression	(34)
	Carboplatin + Pemetrexed
	Carboplatin	636.92 mg	AUC 5 mg/mL	21	4	(35–37)
	Pemetrexed	894 mg	500 mg/m2	21	Up to progression
	Cisplatin + Pemetrexed
	Cisplatin	134 mg	75 mg/m2	21	4	(35–37)
	Pemetrexed	894 mg	500 mg/m2	21	Up to progression
	Carboplatin + Paclitaxel + Bevacizumab
	Carboplatin	764.30 mg	AUC 6 mg/mL	21	6	(35,38)
	Paclitaxel	358 mg	200 mg/m2	21	6
	Bevacizumab	1066 mg	15 mg/Kg	21	Up to progression
Non-ALK diagnosed NSCLC patients	Carboplatin + Pemetrexed
	Carboplatin	636.92 mg	AUC 5 mg/mL	21 days	4 cycles	(35,37,39)
	Pemetrexed	894 mg	500 mg/m2	21 days	Up to progression
	Cisplatin + Pemetrexed
	Cisplatin	134 mg	75 mg/m2	21 days	4 cycles	(35,37,39)
	Pemetrexed	894 mg	500 mg/m2	21 days	Up to progression
	Carboplatin + Paclitaxel + Bevacizumab
	Carboplatin	764.30 mg	AUC 6 mg/mL	21 days	6 cycles	(40,41)
	Paclitaxel	358 mg	200 mg/m2	21 days	6 cycles
	Bevacizumab	1066 mg	15 mg/Kg	21 days	Up to progression
	Pembrolizumab (monotherapy)
	Pembrolizumab	200 mg	200 mg	21 days	Up to progression	(42)
	Carboplatin + Paclitaxel
	Carboplatin	764.30 mg	AUC 6 mg/mL	21 days	6 cycles	(35,43)
	Paclitaxel	358 mg	200 mg/m2	21 days	6 cycles
Non-ALK diagnosed NSCLC patients	Carboplatin + Gemcitabine
	Carboplatin	764.30 mg	AUC 6 mg/mL	21 days	6 cycles	(35,44,45)
	Gemcitabine	1788 mg	1000 mg/m² days 1 and 8 of the cycle	21 days	6 cycles
	Cisplatin + Gemcitabine
	Cisplatin	179 mg	100 mg/m2	21 days	6 cycles	(46,47)
	Gemcitabine	2235 mg	1250 mg/m2 days 1 and 8 of the cycle	21 days	6 cycles
	Carboplatin + Vinorelbine
	Carboplatin	509.53 mg	AUC 4 mg/mL	21 days	3 cycles	(35,44,48)
	Vinorelbine	45 mg	25 mg/m2 days 1 and 8 of the cycle	21 days	3 cycles
	Cisplatin + Vinorelbine
	Cisplatin	179 mg	100 mg/m2	21 days	6 cycles	(35,44,49)
	Vinorelbine	54 mg	30 mg/m2 days 1 and 8 of the cycle	21 days	6 cycles
	Carboplatin + Pemetrexed + Pembrolizumab
	Carboplatin	636.92 mg	AUC 5 mg/mL	21 days	4 cycles	(35,39)
	Pemetrexed	894 mg	500 mg/m2	21 days	Up to progression
	Pembrolizumab	200 mg	200 mg	21 days	Up to progression
	Cisplatin + Pemetrexed + Pembrolizumab
	Cisplatin	134 mg	75 mg/m2	21 days	4 cycles	(35,39)
	Pemetrexed	894 mg	500 mg/m2	21 days	Up to progression
	Pembrolizumab	200 mg	200 mg	21 days	Up to progression
	Nivolumab (monotherapy)
	Nivolumab	240 mg	240mg	14 days	Up to progression	(50)
	Atezolizumab (monotherapy)
	Atezolizumab	840 mg	840 mg	14 days	Up to progression	(51)
	Docetaxel (monotherapy)
	Docetaxel	134 mg	75 mg/m2	21 days	6 cycles	(52,53)
	Docetaxel + nintedanib
	Docetaxel	134 mg	75 mg/m2	21 days	4 cycles	(54–56)
	Nintedanib	400 mg	200 mg twice daily	21 days	Up to progression

ALK: anaplastic lymphoma kinase; AUC: Area under the curve; NSCLC: non-small cell lung cancer.